Free CME from PeerView
Continuing Nursing Education (CNE) Activities
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
StartThis activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 18, 2025; credit is no longer available.
Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice
Media: Enduring Material
Activity Release Date: January 19, 2024
Activity Expiration Date: February 18, 2025
Time to Complete Activity: 90 minutes
Activity Description
Groundbreaking science in personalized therapeutic approaches for advanced
biliary tract cancers (BTCs) has resulted in the expansion of a diverse
management model, empowering oncologists to battle the disease, as emerging
evidence continues to reshape treatment planning based on patient-specific
findings. These developments have led to the approval of several immune-based
and molecularly targeted therapies for the clinical management of advanced
BTCs. Through a case-based discussion, experts will provide valuable insight
on the practical aspects of integrating these new and emerging therapeutic
platforms into your clinical practice.
This Seminars and Tumor Board activity, based on a recent live symposium and
produced in collaboration with the Cholangiocarcinoma Foundation (CCF), pairs
real-world case scenarios with the practice-changing evidence that guides
treatment selection for the management of advanced BTCs. PeerView’s
collaboration with the CCF includes their educational resources and patient
stories to improve patient education, engagement in care, and shared
decision-making.
Target Audience
This activity has been designed to meet the educational needs of oncologists, gastroenterologists, advanced practice clinicians (NPs/PAs), and other relevant healthcare professionals involved in the management of biliary cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of modern and emerging therapeutic approaches, including immunotherapy and targeted platforms, for the management of BTC
- Utilize biomarker findings, current evidence, and guideline recommendations to build individualized treatment regimens for patients with advanced BTC
- Develop team-based strategies to address practical considerations of care, including patient education and AE management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Milind Javle, MD
Professor, Department of Gastrointestinal (GI) Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Milind Javle, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.;
Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation;
BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.;
GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen;
Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis
Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.;
Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co.
Ltd.
Faculty/Planner
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center (All
Regions)
Consortium Chair, Academic and Community Cancer Research United (ACCRU)
Phoenix, Arizona
Tanios Bekaii-Saab, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for (to self) AbbVie; Artiva
Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines;
Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity
Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact
Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.;
GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.;
Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.;
Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio
Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.;
Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation;
Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer;
Seattle Genetics; and Servier Laboratories.
Grant/Research Support from AbGenomics Corporation; Agios
Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer
Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene
Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte
Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati
Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle
Genetics. Research funding to Institution.
Data Safety Monitoring Board for 1Globe Health Institute;
AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai
Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals,
Inc.; and The Valley Hospital.
Other Financial or Material Support from holding patents
WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to
Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CACHEXIA – Licensed to Recursion.
Faculty/Planner
Rachna Shroff, MD, MS, FASCO
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Associate Dean, Clinical and Translational Research, UA COM-T
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
Rachna Shroff, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim;
Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED
Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and
Zymeworks Inc.
Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis,
Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.;
NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael
Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 2/18/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
StartThis activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 17, 2025; credit is no longer available.
Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC
Media: Enduring Material
Activity Release Date: January 18, 2024
Activity Expiration Date: February 17, 2025
Time to Complete Activity: 60 minutes
Activity Description
Despite their established role in the treatment of HR+, HER2- metastatic
breast cancer (MBC) and accumulating evidence supporting their adjuvant use
in HR+, HER2- early breast cancer (EBC), questions still surround CDK4/6
inhibitors and their use. While these agents were historically thought to be
largely similar and interchangeable, evolving data from clinical and
translational studies have shown that CDK4/6 inhibitors are not the same.
They have key differences in their chemical, biologic, pharmacologic, and
clinical features and different toxicity profiles, despite all being orally
bioavailable. Therefore, we must re-evaluate how we approach CDK4/6
inhibitors and integrate them into individualized treatment plans for
patients throughout the disease continuum, as well as consider what that
looks like in the real-world setting and how to make the most of them and
their distinct properties in the frontline setting and beyond?
In this activity, based on a recent live virtual workshop, learners receive
an in-depth, expert assessment of CDK4/6 inhibitors in HR+, HER2- EBC and
MBC, which provides the foundation for case-based discussions and tool-based
demonstrations of algorithmic decision aids designed to guide risk
assessment, candidate selection for therapy, and the optimal delivery of
treatment to reduce the risk of recurrence in individuals with HR+, HER2- EBC
before transitioning to HR+, HER2- MBC to demonstrate patient evaluation,
identify factors for prognostication, and model treatment planning,
selection, and sequencing throughout the advance disease continuum.
Additionally, the panel shares strategies to mitigate and manage common
adverse reactions associated with CDK4/6 inhibitors to improve treatment
adherence and persistence.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with early and metastatic breast cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with HR+, HER2- EBC and MBC via thorough assessment of clinical, pathologic, genomic, and other relevant factors
- Design individualized treatment protocols integrating CDK4/6 inhibitor therapy for patients with HR+, HER2- EBC and MBC based on the latest evidence, guidelines, and tumor/disease characteristics
- Develop team-based strategies to achieve optimal treatment adherence/persistence and prevention/mitigation of AEs associated with different CDK4/6 inhibitors in the treatment of HR+, HER2- EBC and MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD
Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas,
Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.;
Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich
LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly;
Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation;
Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity
Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc;
Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene,
Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou)
Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian
Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis,
Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer
Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics;
eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD
Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM
Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.;
Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.;
Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio;
Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm;
Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics,
Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium
Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals
Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova
Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer;
PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics;
Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay
Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix
Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.;
Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc;
TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.;
Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics;
and Zymeworks Inc. (all paid to institution).
Faculty/Planner
Komal Jhaveri, MD, FACP
Patricia and James Cayne Chair for Junior Faculty
Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging
Center
New York, New York
Komal Jhaveri, MD, FACP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint
Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo
Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals
Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen
Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca;
Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.;
Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita
Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion
Therapeutics; and Zymeworks Inc.
Faculty/Planner
Professor Stephen Johnston, MA, PhD
Professor of Breast Cancer Medicine & Head of Medical Oncology
Consultant Medical Oncologist & Head of The Breast Unit
The Royal Marsden NHS Foundation Trust & The Institute of Cancer
Research
Chelsea, London, United Kingdom
Professor Stephen Johnston, MA, PhD, has a financial interest/relationship
or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis
Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and
Sanofi.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche
Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and
Puma Biotechnology, Inc.
Speakers Bureau participant with AstraZeneca; Eisai Inc.; F.
Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-015-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/17/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD), and a
score of 75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
StartThis activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 16, 2025; credit is no longer available.
From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care
Media: Enduring Material
Activity Release Date: January 17, 2024
Activity Expiration Date: February 16, 2025
Time to Complete Activity: 60 minutes
Activity Description
Can you move from resistance to resilience with BTK inhibitors (BTKi) in relapsed/refractory chronic lymphocytic leukemia (CLL)? Learn how to overcome the well-recognized barriers—including therapeutic intolerance and disease progression—to effective sequential care by joining CLL experts in this case-based educational program. In this activity, developed in collaboration with CLL Society, the experts provide guidance on integrating new sequential BTKi options into everyday clinical practice and share patient scenarios designed to showcase skills that can help overcome medical challenges associated with continuous BTKi therapy over multiple lines of treatment. Don’t miss this opportunity to get back to resilient care with BTKi options in CLL!
Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
- Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
- Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
- Employ team-based approaches to address practical aspects of CLL care when using BTKi, including care coordination, formulary planning, patient education, dosing, and management of treatment-related AEs
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Meghan C. Thompson, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo
Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca;
BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics.
Research funding goes to Institution.
Co-Chair/Planner
Catherine C. Coombs, MD
Associate Clinical Professor
University of California, Irvine
Orange, California
Catherine C. Coombs, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene
Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen
Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals,
Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene,
Inc.; and Genentech, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-011-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/16/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
StartThis activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 11, 2025; credit is no longer available.
Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team
Media: Enduring Material
Activity Release Date: January 12, 2024
Activity Expiration Date: January 11, 2025
Time to Complete Activity: 45 minutes
Activity Description
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
- Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
John L. Marshall, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca;
Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer
Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose;
Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical
Company Limited; and Zcurex.
Other Financial or Material Support Executive role
for Indivumed GmbH.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
The activity titled “Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team” has been registered to offer 0.75 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-066-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 1/11/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of
75% or higher is needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
StartThis activity expired on January 9, 2025; credit is no longer available.
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: January 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
With an increasing body of evidence supporting improved approaches for
treating gastroesophageal cancers, oncology professionals can now look beyond
conventional treatment options. Today’s clinicians can integrate personalized
treatment approaches, including immunotherapy and targeted strategies, based
on patient- and disease-specific factors for a superior design of upfront and
sequential therapeutic management.
In this educational activity, experts use illustrative case studies to
provide an overview of the clinical evidence and guideline recommendations
for immunotherapy and targeted agents for gastroesophageal cancers,
strategies for creating personalized treatment plans, and guidance on using a
holistic and team-based approach to address potential challenges associated
with modern therapies.
Target Audience
This activity has been designed to meet the educational needs of oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with gastric/GEJ cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest clinical evidence and guideline recommendations supporting the utilization of immunotherapy and targeted agents for patients with gastric/GEJ cancer
- Develop personalized treatment plans for patients with gastric/GEJ cancer based on current clinical evidence, guideline updates, and patient-specific factors
- Integrate a holistic, team-based approach to prevent and address AEs associated with modern systemic therapies for patients with gastric/GEJ cancer to prevent treatment interruptions/disruptions to care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jaffer A. Ajani, MD, FASCO
Professor of Medicine, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for American Cancer Society; Amgen Inc.;
Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Servier.
Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.;
Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz
Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company
Limited; Transcenta; and Zymeworks Inc.
Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca;
BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co,
Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks
Inc.
Co-Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant
Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co.,
Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics
(ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on January 9, 2025; credit is no longer available.
Looking Beyond the Horizon in Gastroesophageal Cancers: Updated Evidence on How Systemic Therapies Are Redefining Care
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: January 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
With an increasing body of evidence supporting improved approaches for
treating gastroesophageal cancers, oncology professionals can now look beyond
conventional treatment options. Today’s clinicians can integrate personalized
treatment approaches, including immunotherapy and targeted strategies, based
on patient- and disease-specific factors for a superior design of upfront and
sequential therapeutic management.
In this educational activity, experts use illustrative case studies to
provide an overview of the clinical evidence and guideline recommendations
for immunotherapy and targeted agents for gastroesophageal cancers,
strategies for creating personalized treatment plans, and guidance on using a
holistic and team-based approach to address potential challenges associated
with modern therapies.
Target Audience
This activity has been designed to meet the educational needs of oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with gastric/GEJ cancer.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the latest clinical evidence and guideline recommendations supporting the utilization of immunotherapy and targeted agents for patients with gastric/GEJ cancer
- Develop personalized treatment plans for patients with gastric/GEJ cancer based on current clinical evidence, guideline updates, and patient-specific factors
- Integrate a holistic, team-based approach to prevent and address AEs associated with modern systemic therapies for patients with gastric/GEJ cancer to prevent treatment interruptions/disruptions to care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jaffer A. Ajani, MD, FASCO
Professor of Medicine, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jaffer A. Ajani, MD, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for American Cancer Society; Amgen Inc.;
Astellas Pharma Inc.; BeiGene, Inc.; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co.,
Inc.; Novartis Pharmaceuticals Corporation; and Servier.
Grant/Research Support from Amgen Inc.; Astellas Pharma Inc.;
Bristol Myers Squibb; Daiichi Sankyo, Inc., Delta-Fly Pharma, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Jazz
Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation;
Prolinx, Inc.; Taiho Pharmaceutical Co, Ltd.; Takeda Pharmaceutical Company
Limited; Transcenta; and Zymeworks Inc.
Honoraria from Amgen Inc.; Astellas Pharma Inc.; AstraZeneca;
BeiGene, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo,
Inc.; Eisai Inc; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Merck & Co,
Inc.; Novartis Pharmaceuticals Corporation; Servier; and Zymeworks
Inc.
Co-Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; EMD Serono Inc.; Geneos Therapeutics, Inc.; GlaxoSmithKline; Guardant
Health; Imugene Limited; Inspirna, Inc.; Lilly; Lynx Health; Merck & Co.,
Inc.; Mersana Therapeutics Inc.; Pfizer; Seagen Inc.; Silverback Therapeutics
(ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from Astellas, AstraZeneca, BeiGene, Daiichi Sankyo, Inc., and Merck & Co., Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 1/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
StartThis activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
This activity expired on February 9, 2025; credit is no longer available.
Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC
Media: Enduring Material
Activity Release Date: January 10, 2024
Activity Expiration Date: February 9, 2025
Time to Complete Activity: 60 minutes
Activity Description
The standard of care for patients with HR+, HER2- locally advanced unresectable or metastatic breast cancer (MBC) in the first-line setting involves endocrine therapy in combination with a CDK4/6 inhibitor. However, questions persist regarding the optimal use of each CDK4/6 inhibitor in first- and later-line settings. Ongoing research, fortunately, is providing new insights into the use of CDK4/6 inhibitors. Additionally, a number of investigational therapies with the potential to change clinical practice are showing great promise, with some recently approved in the metastatic setting. These investigational therapies include novel oral SERDs, ATK inhibition, and antibody–drug conjugates, such as those targeting HER2 and TROP2. With these therapies proving their clinical potential, it is essential to learn how to best integrate them into the current treatment arsenal. Furthermore, various patient- and disease-related factors such as age, HR status, metastatic sites, visceral involvement, endocrine resistance, tumor grade, disease-free interval, and molecular profile must be considered for optimal individualized therapy as well. In this PeerView Live virtual workshop, presented through a case-based framework, leading experts review the latest clinical evidence and provide practical strategies on navigating the complexities of clinical decision-making and selection and sequencing of therapies. The panel also addresses the nuances of treatment delivery and best practices for mitigating and managing adverse events associated with CDK4/6 inhibitors to help patients with HR+, HER2- MBC achieve the best possible outcomes.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR+, HER2- MBC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest efficacy and safety data supporting the use of CDK4/6 inhibitors, as well as new and emerging treatment options for patients with HR+, HER2- MBC, considering their evolving roles in clinical practice
- Develop individualized treatment plans that integrate CDK4/6 inhibitor therapy for patients with HR+, HER2- MBC, based on the latest evidence, guidelines, and assessment of drug-, tumor/disease-, and patient-related factors
- Implement team-based strategies to achieve optimal treatment adherence and persistence, as well as prevent and mitigate adverse events associated with different CDK4/6 inhibitors in the management of HR+, HER2- MBC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agendia;
Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals,
Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.;
Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics,
Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.;
Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.;
Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre
Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis;
Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics,
Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho
Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Sara M. Tolaney, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for 4D pharma plc; Aadi
Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.;
Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi
Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech,
Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz
Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera;
Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi;
Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini
Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis;
Zetagen; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers
Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly;
Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis
Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.
Other Financial or Material Support from Steering
committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-004-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/9/2025. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a
completed activity evaluation form and will be emailed to you upon
completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of
your emailed certificate, please contact via email at
info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are
required in their entirety as well as your Board Unique ID number, DOB
(MM/DD), and a score of 75% or higher is needed to obtain MOC/CC
credit.
For nurses, the post-test and evaluation form are required in
their entirety and a score of 75% or higher is needed to obtain Nursing
Continuing Professional Development (NCPD) credit. There are no prerequisites
and there is no fee to participate in this activity or to receive NCPD
credit. Statements of Credit are awarded upon successful completion of the
post-test and evaluation form.
For pharmacists, upon receipt of the completed activity
evaluation form, you will receive an email from email@email.peerviewpress.com
within 2 weeks with a link and directions to submit your credit to the NABP
CPE Monitor Service. PVI, PeerView Institute for Medical Education, will
accept your completed evaluation form for up to 30 days and will report your
participation to the NABP only if you provide your NABP e-Profile number and
date of birth. Within 6 weeks, you can view your participation record at the
NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2024, PeerView
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
StartThis activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, an expert discusses identifying barriers that threaten ending the HIV epidemic, current and emerging treatment options in HIV management, and ways to personalize treatment for patients living with HIV to improve outcomes and adherence.
Target Audience
This activity has been designed to meet the educational needs of HIV care providers, primary care providers and general practitioners, advanced practice providers, nurses, pharmacists, and other professionals involved in the care of patients living with HIV.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Identify patient barriers that may contribute to poor persistence with HIV treatment
- Counsel patients living with HIV about the benefits and flexibility of current and emerging options in treatment and the importance of remaining adherent to therapy
- Personalize treatment for patients living with HIV based on therapeutic mechanism of action, route of administration, efficacy, safety, and resistance profiles, considering each patient’s individual needs across the age span (adolescence, child-bearing years, aged >65 years)
- Implement team-based HIV management strategies that ensure health equity, access and adherence to treatment, and ongoing monitoring for resistance
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin
Professor of Infection and Inequities
Queen Mary University of London
Barts Health NHS Trust
London, England, United Kingdom
Professor Chloe Orkin has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck
Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV
Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme;
and ViiV Healthcare group of companies.
Patient Advocate/Planner
Shawnte' Spriggs
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.
Patient Advocate/Planner
Donald Young
Donald Young has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-069-H02-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
StartThis activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 12, 2024; credit is no longer available.
Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making
Media: Enduring Material
Activity Release Date: December 13, 2023
Activity Expiration Date: December 12, 2024
Time to Complete Activity: 30 minutes
Activity Description
The establishment of immunotherapy-based regimens in the modern treatment
paradigm for upper GI Cancers, including gastric and gastroesophageal
junction (GEJ) cancers, is placing increased importance on close
collaboration between the clinical care team and patients and caregivers, to
promote engagement in a process of informed shared decision-making (SDM) when
selecting treatment plans that are tailored to patient-specific needs,
values, and preferences.
In this PeerView activity, an oncologist, who is an expert in GI cancers,
will present practice-changing evidence for integrating immunotherapy
approaches into treatment plans; give insights on the rationale and benefits
of engaging patients in informed shared decision-making when choosing
treatment options; and explore the available tools when making informed
shared decisions about immuno-oncology strategies as part of a team-based,
equitable management approach, using the CheckMate -649 plain language
summary as an example that can be downloaded for your use. Don’t miss this
unique opportunity to enhance your skills in patient engagement to promote
SDM in your practice!
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other care team professionals involved in the treatment of patients with upper GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe current evidence-based, guideline-recommended protocols for integrating immuno-oncology approaches into treatment plans for patients with upper GI cancers across disease settings
- Explain the benefits of engaging patients with upper GI cancers in informed shared decision-making by the healthcare team when choosing a treatment option including the effects on patient engagement in the selected treatment plan
- Utilize available tools including plain language summaries when making informed shared decisions about including immuno-oncology strategies as part of a team-based, equitable management approach to upper GI malignancies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD
Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
*This activity was developed with Yelena Y. Janjigian, MD, and is not
affiliated in any capacity with Memorial Sloan Kettering Cancer Center.
Yelena Y. Janjigian*, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus
Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea
Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo
Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer;
Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and
Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer
HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival;
Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.;
Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and
U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-073-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/12/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
StartThis activity expired on December 10, 2024; credit is no longer available.
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
Media: Enduring Material
Activity Release Date: December 11, 2023
Activity Expiration Date: December 10, 2024
Time to Complete Activity: 30 minutes
Activity Description
Antibody–drug conjugates (ADCs) are associated with positive clinical trial outcomes and regulatory approvals in the treatment of patients with gynecologic malignancies such as cervical, ovarian, and endometrial cancers. As patient care shifts from largely chemotherapy-focused approaches to modern therapeutics, professionals must stay informed on the latest data supporting ADCs and best practices for using ADC-based regimens in the clinic. In this video-based activity, expert faculty review evidence on the use of ADCs in gynecologic cancers, provide strategies for developing individualized treatment plans that incorporate ADC-based regimens (including via clinical trial enrollment), and offer guidance on team-based approaches to managing AEs in patients with gynecologic cancers undergoing treatment with ADCs.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, and other healthcare professionals involved in the care of patients with gynecologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the properties, mechanisms of action, and latest clinical evidence of validated and emerging antibody–drug conjugates (ADCs) in gynecologic cancers
- Select approved and emerging ADCs for the treatment of patients with gynecologic cancer within the context of clinical practice or through clinical trial participation
- Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with gynecologic cancer receiving ADC therapy and provide education, guidance, and counseling for optimal use
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
University of Arizona College of Medicine
Creighton University School of Medicine
Phoenix, Arizona
Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune
Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar,
LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab
A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.;
Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.;
Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics;
Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH;
OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals,
Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento
Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC;
VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from US Oncology Research, LLC.
Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F.
Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.;
and TESARO, Inc./GlaxoSmithKline.
Faculty/Planner
Ana Oaknin, MD, PhD
Head of Gynaecological Cancer Program
Medical Oncology Department
Vall d'Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis
Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.;
EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S;
GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de
Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.;
Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs,
Inc.; and Sutro Biopharma, Inc.
Grant/Research Support from AbbVie Deutschland; Advaxis Inc.;
Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb;
Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.;
Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar
SA; Regeneron Pharmaceuticals Inc; and Tesaro.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/10/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 10, 2024; credit is no longer available.
The ABCs of ADCs for Gynecologic Cancer: Expert Insights on Effective Implementation and Practical Tips for Use in Patients With Cervical, Ovarian, or Endometrial Cancer
Media: Enduring Material
Activity Release Date: December 11, 2023
Activity Expiration Date: December 10, 2024
Time to Complete Activity: 30 minutes
Activity Description
Antibody–drug conjugates (ADCs) are associated with positive clinical trial outcomes and regulatory approvals in the treatment of patients with gynecologic malignancies such as cervical, ovarian, and endometrial cancers. As patient care shifts from largely chemotherapy-focused approaches to modern therapeutics, professionals must stay informed on the latest data supporting ADCs and best practices for using ADC-based regimens in the clinic. In this video-based activity, expert faculty review evidence on the use of ADCs in gynecologic cancers, provide strategies for developing individualized treatment plans that incorporate ADC-based regimens (including via clinical trial enrollment), and offer guidance on team-based approaches to managing AEs in patients with gynecologic cancers undergoing treatment with ADCs.
Target Audience
This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, and other healthcare professionals involved in the care of patients with gynecologic cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the properties, mechanisms of action, and latest clinical evidence of validated and emerging antibody–drug conjugates (ADCs) in gynecologic cancers
- Select approved and emerging ADCs for the treatment of patients with gynecologic cancer within the context of clinical practice or through clinical trial participation
- Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with gynecologic cancer receiving ADC therapy and provide education, guidance, and counseling for optimal use
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
University of Arizona College of Medicine
Creighton University School of Medicine
Phoenix, Arizona
Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Adaptimmune
Therapeutics plc.; Agenus Inc.; Akeso Biopharma Co., Ltd.; Amgen Inc.;
Aravive; AstraZeneca; Bayer Corporation; Clovis Oncology; Eisai Inc.; Elevar,
LLC; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Genmab
A/S/Seagen Inc.; The GOG Foundation Inc; Gradalis, Inc.; ImmunoGen, Inc.;
Iovance Biotherapeutics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.;
Karyopharm; Laekna Therapeutics; Merck & Co., Inc.; Mersana Therapeutics;
Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Novocure GmbH;
OncoC4, Inc.; Panavance Therapeutics Inc.; Pfizer; Pieris Pharmaceuticals,
Inc.; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; Sorrento
Therapeutics, Inc.; TESARO, Inc./GlaxoSmithKline; US Oncology Research, LLC;
VBL Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from US Oncology Research, LLC.
Speaker for AstraZeneca; Clovis Oncology; Eisai Inc.; F.
Hoffmann-La Roche Ltd./Genentech, Inc.; Merck & Co., Inc.;
and TESARO, Inc./GlaxoSmithKline.
Faculty/Planner
Ana Oaknin, MD, PhD
Head of Gynaecological Cancer Program
Medical Oncology Department
Vall d'Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Ana Oaknin, MD, PhD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Agenus Inc.; AstraZeneca; Clovis
Oncology; Corcept Therapeutics; Deciphera Pharmaceuticals; Eisai Co., Ltd.;
EMD Serono; Exelisis, Inc.; F. Hoffmann-La Roche; Genmab A/S;
GlaxoSmithKline; ImmunoGen, Inc.; iTeos Therapeutics; Merck Sharp & Dohme de
Espana SA; Mersana Therapeutics; Novocure GmbH; OncXerna Therapeutics, Inc.;
Pharma Mar SA; Regeneron Pharmaceuticals Inc.; Seagen, Inc.; Shattuck Labs,
Inc.; and Sutro Biopharma, Inc.
Grant/Research Support from AbbVie Deutschland; Advaxis Inc.;
Aeterna Zentaris; Amgen Inc.; Aprea Therapeutics AB; Bristol Myers Squibb;
Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche; ImmunoGen, Inc.;
Merck Sharp & Dohme de Espana SA; Millennium Pharmaceuticals Inc.; Pharma Mar
SA; Regeneron Pharmaceuticals Inc; and Tesaro.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., and Seagen and Genmab.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 12/10/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
StartThis activity expired on December 29, 2024; credit is no longer available.
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: December 29, 2024
Time to Complete Activity: 90 minutes
Activity Description
Since the first approval of an immune checkpoint inhibitor (ICI) in 2015,
the evolution of immunotherapy has drastically changed the lung cancer
treatment landscape. There are now many monotherapy and combinatorial options
available for patients with metastatic NSCLC, allowing individualized therapy
according to various factors. In locally advanced unresectable stage III
NSCLC, consolidation immunotherapy following chemoradiation is routinely
used, and other ICI-based multimodal approaches are being investigated in
clinical trials. Expanding to earlier stages, ICIs have received regulatory
approvals in adjuvant, neoadjuvant, and perioperative (both adjuvant and
neoadjuvant) settings, changing the standards of care for resectable stage
I-III NSCLC. Ongoing studies are expected to further broaden the impact and
refine the use of immunotherapy in lung cancer in the near future.
This PeerView educational activity, based on a recent live symposium,
provides comprehensive guidance on the evidence-based integration and
practical use of current and emerging immunotherapy options as well as
leveraging multidisciplinary and interprofessional collaboration in the
context of new requirements and changing best practices to improve patient
outcomes throughout the NSCLC disease continuum. Experts present illustrative
case scenarios to frame in-depth reviews and interpretations of evidence
supporting the use of immunotherapies in NSCLC to equip participants with the
tools and strategies needed to improve patient outcomes.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest evidence supporting the use of current and emerging ICIs and combinations in metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Determine the most appropriate ICI-based treatment approaches for eligible patients with metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Implement best practices for multidisciplinary and interprofessional collaboration and patient-centered care to optimally integrate immunotherapies throughout the NSCLC disease continuum, maximize their benefits, and minimize their risks during treatment and survivorship
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew A. Gubens, MD, MS, FASCO
Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca;
Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F.
Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health;
Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and
Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson &
Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed
Pharmaceuticals, Inc.; and Trizell. Research funding to
institution.
Faculty/Planner
Jessica Donington, MD
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois
Jessica Donington, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co.,
Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Faculty/Planner
Elaine Shum, MD
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine
Thoracic Medical Oncologist
NYU Perlmutter Cancer Center
New York, New York
Elaine Shum, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AstraZeneca; Blueprint Medicines
Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead
Sciences, Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from DELFI Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/29/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 29, 2024; credit is no longer available.
Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: December 29, 2024
Time to Complete Activity: 90 minutes
Activity Description
Since the first approval of an immune checkpoint inhibitor (ICI) in 2015,
the evolution of immunotherapy has drastically changed the lung cancer
treatment landscape. There are now many monotherapy and combinatorial options
available for patients with metastatic NSCLC, allowing individualized therapy
according to various factors. In locally advanced unresectable stage III
NSCLC, consolidation immunotherapy following chemoradiation is routinely
used, and other ICI-based multimodal approaches are being investigated in
clinical trials. Expanding to earlier stages, ICIs have received regulatory
approvals in adjuvant, neoadjuvant, and perioperative (both adjuvant and
neoadjuvant) settings, changing the standards of care for resectable stage
I-III NSCLC. Ongoing studies are expected to further broaden the impact and
refine the use of immunotherapy in lung cancer in the near future.
This PeerView educational activity, based on a recent live symposium,
provides comprehensive guidance on the evidence-based integration and
practical use of current and emerging immunotherapy options as well as
leveraging multidisciplinary and interprofessional collaboration in the
context of new requirements and changing best practices to improve patient
outcomes throughout the NSCLC disease continuum. Experts present illustrative
case scenarios to frame in-depth reviews and interpretations of evidence
supporting the use of immunotherapies in NSCLC to equip participants with the
tools and strategies needed to improve patient outcomes.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the latest evidence supporting the use of current and emerging ICIs and combinations in metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Determine the most appropriate ICI-based treatment approaches for eligible patients with metastatic, stage III unresectable, and stage I-III resectable NSCLC
- Implement best practices for multidisciplinary and interprofessional collaboration and patient-centered care to optimally integrate immunotherapies throughout the NSCLC disease continuum, maximize their benefits, and minimize their risks during treatment and survivorship
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Matthew A. Gubens, MD, MS, FASCO
Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca;
Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F.
Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health;
Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and
Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson &
Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed
Pharmaceuticals, Inc.; and Trizell. Research funding to
institution.
Faculty/Planner
Jessica Donington, MD
Professor of Surgery
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois
Jessica Donington, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers
Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co.,
Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb;
Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Faculty/Planner
Elaine Shum, MD
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine
Thoracic Medical Oncologist
NYU Perlmutter Cancer Center
New York, New York
Elaine Shum, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AstraZeneca; Blueprint Medicines
Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead
Sciences, Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from DELFI Diagnostics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent educational grant from AstraZeneca.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/29/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
StartThis activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 29, 2024; credit is no longer available.
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms
Media: Enduring Material
Activity Release Date: November 30, 2023
Activity Expiration Date: November 29, 2024
Time to Complete Activity: 60 minutes
Activity Description
Although innovative therapeutics have led to better overall outcomes, multiple myeloma (MM) remains an incurable disease that presents a range of challenges, particularly in relapsed/refractory (RR) settings. In this educational activity, PeerView partners with the HealthTree Foundation for Multiple Myeloma to address these challenges by bringing together MM experts to demonstrate how the healthcare team can enhance care through the judicious selection and sequencing of CD38 antibodies in RRMM. Mixing foundational evidence and case-based teaching, the experts provide guidance on how to sequence CD38 options based on prior lines of therapy, high-risk features, and comorbidities, while addressing dosing, scheduling, and safety considerations associated with CD38 platforms. Watch this CME/MOC/NCPD/IPCE activity today and become part of the A-team against RRMM in your community!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, allied health professionals, nurses, and other clinicians involved in the care of patients with multiple myeloma.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence supporting the use of CD38-based platforms in RRMM
- Implement team-based strategies for sequencing CD38 platforms in RRMM based on prior lines of therapy, patient characteristics, comorbidities, and other clinically-relevant factors
- Develop collaborative strategies to address issues such as dosing/scheduling and safety considerations associated with the use of CD38 platforms in RRMM
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD
Interim Chief, Division of Hematology/Oncology
Director, Adult Blood and Marrow Transplantation Program
Professor of Clinical Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Thomas G. Martin, III, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen
Pharmaceuticals, Inc.; and Sanofi.
Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Sanofi.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
StartThis activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 27, 2024; credit is no longer available.
Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care
Expert commentary is based on data presented at the European Society for
Medical Oncology (ESMO) Congress 2023.
PeerView is an independent publisher of conference news and medical education
programs.
Media: Enduring Material
Activity Release Date: November 28, 2023
Activity Expiration Date: November 27, 2024
Time to Complete Activity: 45 minutes
Activity Description
Emerging evidence supporting modern targeted strategies for the management
of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has
led to the development of several agents to personalize therapy for patients
with HER2-expressing malignancies.
In collaboration with the Cholangiocarcinoma Foundation, this activity will
provide the latest updates on evolving, evidence-based practice standards for
HER2-targeting agents, including emerging data arising from the 2023 ESMO
Congress. Through a conversational exchange of ideas combined with
compelling, case-based instruction, experts will engage in discussions of
real-world patient scenarios to illustrate best practices for the management
of HER2-expressing BTC and GEA, including overcoming barriers associated with
baseline molecular testing for personalized therapy selection.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, gastrointestinal oncologists, hepatobiliary surgeons, hepatologists, gastroenterologists, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals involved in the care of patients with GI cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize current evidence supporting targeted agents for the management of HER2-positive GI cancers, including safety/efficacy profiles, dosing considerations, and their role in current treatment protocols
- Develop individualized treatment plans based on molecular findings, current and emerging clinical evidence, and guideline recommendations when managing patients with HER2-expressing BTC and GEA
- Integrate team-based strategies to prevent and manage well-documented adverse events associated with HER2-targeting therapies when managing patients with BTC and GEA
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD
Head, Medical Oncology Department, Vall d’Hebron University Hospital
(HUVH)
Director, Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Josep Tabernero, MD, PhD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim
International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai
Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd;
Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly;
Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.;
NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc;
Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S;
Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda
Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics,
Pangaea Oncology and 1TRIALSP.
Co-Chair/Planner
Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas
Shubham Pant, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer
Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.;
Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and
Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus
Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim
International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering
Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly;
Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals
Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All
goes to Institution.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-072-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 11/27/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
StartThis activity expired on November 26, 2024; credit is no longer available.
Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
Activity Description and Educational Objectives
For people with obesity, early intervention is central to reducing the
risk for related comorbidities. However, almost half of these people are
never formally diagnosed, nor do they ever receive care specifically
targeting their obesity. But why? Obesity can be challenging to discuss with
patients due to clinician discomfort or uncertainty, lack of training, or
personal biases. For these reasons and more, there is no denying that
managing obesity is complex. Characterizing obesity as a chronic disease
resulting from metabolic adaptation rather than a personal failing means we
can reframe how we approach its treatment.
This latest educational opportunity on obesity from PeerView, developed in
collaboration with the University of Florida College of Medicine, teaches
primary care providers how to practice what they preach and inspire change.
By the end of this activity, you will have gained knowledge to prioritize
obesity management in the primary care setting, learn strategies to
effectively discuss anti-obesity medications, and get expert tools to modify
obesity management plans to meet individual long-term goals. This informative
activity features expert faculty, a video segment depicting patient-provider
conversations (thanks to skilled actors with the University of Delaware
Healthcare Theater Program), and the latest on practical skills and clinical
data.
Upon completion of this activity, participants should be better able to:
- Initiate nonbiased discussions with patients early in the course of obesity to establish and achieve realistic weight loss goals to prevent the development and progression of obesity-related comorbidities
- Evaluate the mechanisms of action, efficacy, and safety of anti-obesity medications as adjunctive treatment to support behavior and lifestyle efforts towards achieving and maintaining weight loss over the long term and to minimize the impact of obesity-related comorbidities
- Personalize treatment plans to avoid or minimize comorbidities and optimize long-term outcomes for people with obesity consistent with current guideline recommendations, available evidence, and according to shared decision-making principles
Target Audience
This activity has been designed to meet the educational needs of US-based primary care providers including physicians, NPs, PAs, and other healthcare professionals involved in the care of people with obesity.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME credit and 75% or higher to obtain NCPD credit. There
are no prerequisites and there is no fee to participate in this activity or
to receive CME/NCPD/AAPA credit. Statements of Credit are awarded upon
successful completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: November 27, 2023 - November 26, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Co-Chair & Presenter
W. Troy Donahoo, MD, FTOS
Professor and Chief
Division of Endocrinology, Diabetes & Metabolism
Department of Medicine
University of Florida
Gainesville, Florida
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair & Presenter
Amy J. Sheer, MD, MPH
Assistant Professor of Medicine
Diplomat of the American Board of Obesity Medicine
Department of Medicine
Division of Internal Medicine
University of Florida College of Medicine
Gainesville, Florida
Amy J. Sheer, MD, MPH, has no financial interests/relationships or
affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Patient Actor
Gerre Garrett Pierce
Actors of Health Care Theatre have nothing to disclose.
Medical Directors
Angela McIntosh, PhD
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Margery Tamas, MPH
Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Partners
Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change
Activity Description and Educational Objectives
For people with obesity, early intervention is central to reducing the
risk for related comorbidities. However, almost half of these people are
never formally diagnosed, nor do they ever receive care specifically
targeting their obesity. But why? Obesity can be challenging to discuss with
patients due to clinician discomfort or uncertainty, lack of training, or
personal biases. For these reasons and more, there is no denying that
managing obesity is complex. Characterizing obesity as a chronic disease
resulting from metabolic adaptation rather than a personal failing means we
can reframe how we approach its treatment.
This latest educational opportunity on obesity from PeerView, developed in
collaboration with the University of Florida College of Medicine, teaches
primary care providers how to practice what they preach and inspire change.
By the end of this activity, you will have gained knowledge to prioritize
obesity management in the primary care setting, learn strategies to
effectively discuss anti-obesity medications, and get expert tools to modify
obesity management plans to meet individual long-term goals. This informative
activity features expert faculty, a video segment depicting patient-provider
conversations (thanks to skilled actors with the University of Delaware
Healthcare Theater Program), and the latest on practical skills and clinical
data.
Upon completion of this activity, participants should be better able to:
- Initiate nonbiased discussions with patients early in the course of obesity to establish and achieve realistic weight loss goals to prevent the development and progression of obesity-related comorbidities
- Evaluate the mechanisms of action, efficacy, and safety of anti-obesity medications as adjunctive treatment to support behavior and lifestyle efforts towards achieving and maintaining weight loss over the long term and to minimize the impact of obesity-related comorbidities
- Personalize treatment plans to avoid or minimize comorbidities and optimize long-term outcomes for people with obesity consistent with current guideline recommendations, available evidence, and according to shared decision-making principles
Target Audience
This activity has been designed to meet the educational needs of US-based primary care providers including physicians, NPs, PAs, and other healthcare professionals involved in the care of people with obesity.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and
complete the post-test and evaluation form. A score of 80% or higher is
needed to obtain CME credit and 75% or higher to obtain NCPD credit. There
are no prerequisites and there is no fee to participate in this activity or
to receive CME/NCPD/AAPA credit. Statements of Credit are awarded upon
successful completion of the post-test and evaluation form.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Media: Enduring Material
Release and Expiration Dates: November 27, 2023 - November 26, 2024
Time to Complete: 60 minutes
Faculty and Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.
Co-Chair & Presenter
W. Troy Donahoo, MD, FTOS
Professor and Chief
Division of Endocrinology, Diabetes & Metabolism
Department of Medicine
University of Florida
Gainesville, Florida
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.
Co-Chair & Presenter
Amy J. Sheer, MD, MPH
Assistant Professor of Medicine
Diplomat of the American Board of Obesity Medicine
Department of Medicine
Division of Internal Medicine
University of Florida College of Medicine
Gainesville, Florida
Amy J. Sheer, MD, MPH, has no financial interests/relationships or
affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Patient Actor
Gerre Garrett Pierce
Actors of Health Care Theatre have nothing to disclose.
Medical Directors
Angela McIntosh, PhD
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.
Margery Tamas, MPH
Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.
Accreditation, Credit, and Support
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Physicians
The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Partners
Components of this activity have been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of
products or devices that are not currently labeled for use by the FDA.
Faculty members have been advised to disclose to the audience any reference
to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage
of these products or uses in our reports. No responsibility is taken for
errors or omissions in reports. For approved prescribing information, please
consult the manufacturer’s product labeling.
About This CME/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, and the University of
Florida College of Medicine are responsible for the selection of this
activity’s topics, the preparation of editorial content, and the distribution
of this activity. Our activities may contain references to unapproved
products or uses of these products in certain jurisdictions. The preparation
of PeerView activities is supported by educational grants subject to written
agreements that clearly stipulate and enforce the editorial independence of
PVI and the University of Florida College of Medicine.
The materials presented here are used with the permission of the authors
and/or other sources. These materials do not necessarily reflect the views of
PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
StartThis activity expired on November 12, 2024; credit is no longer available.
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
Media: Enduring Material
Activity Release Date: November 13, 2023
Activity Expiration Date: November 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, experts discuss the underlying pathophysiology involved in the development of plaque psoriasis, focusing on IL-23 signaling and the targeting of the TYK2 kinase, and patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as well as personalized management plans for patients with psoriasis.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other healthcare professionals involved in the care of patients with psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the underlying pathophysiology involved in the development of plaque psoriasis, specifically focusing on IL-23 signaling and the selective targeting of the TYK2 kinase
- Select patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as supported by the latest efficacy and safety data
- Formulate personalized management plans for patients with psoriasis utilizing a team approach while addressing individuals’ treatment goals and preferences as well as inequities and disparities in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California, Los Angeles (UCLA)
Los Angeles, California
April W. Armstrong, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira,
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical;
Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals;
Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant
Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi;
and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer;
Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until . PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 12, 2024; credit is no longer available.
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
Media: Enduring Material
Activity Release Date: November 13, 2023
Activity Expiration Date: November 12, 2024
Time to Complete Activity: 60 minutes
Activity Description
In this activity, experts discuss the underlying pathophysiology involved in the development of plaque psoriasis, focusing on IL-23 signaling and the targeting of the TYK2 kinase, and patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as well as personalized management plans for patients with psoriasis.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other healthcare professionals involved in the care of patients with psoriasis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Explain the underlying pathophysiology involved in the development of plaque psoriasis, specifically focusing on IL-23 signaling and the selective targeting of the TYK2 kinase
- Select patients with psoriasis who would benefit from treatment involving TYK2 inhibition, as supported by the latest efficacy and safety data
- Formulate personalized management plans for patients with psoriasis utilizing a team approach while addressing individuals’ treatment goals and preferences as well as inequities and disparities in care
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH
Professor and Chief of Dermatology
University of California, Los Angeles (UCLA)
Los Angeles, California
April W. Armstrong, MD, MPH, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira,
Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical;
Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals
Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals;
Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant
Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.
Co-Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics,
Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers
Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals,
Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi;
and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim
Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences,
Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer;
Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until . PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
StartThis activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on December 9, 2024; credit is no longer available.
Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: December 9, 2024
Time to Complete Activity: 90 minutes
Activity Description
Antibody–drug conjugates (ADCs), including those targeting HER2, HER3, and
TROP2, are an exciting new class of therapies that selectively deliver
cytotoxic payloads to cancer cells. Recent regulatory approvals have cemented
the role of ADCs in the treatment of various solid tumors, motivating further
innovation to expand their use in other tumor types and disease settings. The
new ADC era brings hope to patients with unmet needs, and keeping current
with the latest advances, applying evidence to practice, mitigating adverse
events, and identifying patients eligible to received ADCs in practice and
clinical trials are more important than ever.
This PeerView educational activity, based on a recent live symposium, offers
expert guidance on how to interpret and apply the latest evidence on HER2-,
HER3-, TROP2-targeting, and other ADCs in the treatment of different solid
tumors. Strategies for decision-making and optimizing outcomes for patients
with cancer who may benefit from ADCs are also discussed, and case-based
clinical scenarios highlight the practical considerations related to using
ADCs in real-world care settings.
Target Audience
This activity has been designed to meet the educational needs of advanced practitioners in oncology and other clinicians involved in the management of patients with solid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the rationale for use, mechanisms of action, safety and efficacy profiles based on available clinical evidence, and evolving clinical roles of the different ADCs targeting HER2, HER3, and TROP2 in solid tumors
- Identify patients with solid tumors who might benefit from HER2-, HER3-, and TROP2-targeting ADCs in clinical practice or through clinical trial enrollment
- Integrate approved and emerging therapies such as HER2-, HER3-, and TROP2-targeting ADCs safely and effectively into treatment plans of eligible patients with solid tumors according to the latest evidence and guidelines
- Implement best practices for identifying and managing treatment-related adverse events in patients with solid tumors receiving ADC therapies to promote optimal adherence, outcomes, and quality of life
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen
Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz
Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda
Pharmaceutical Company Limited.
Faculty/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals
Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME
and OncLive.
Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN
Senior Advanced Practice Provider
Abramson Cancer Center at Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial
interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Nurse Practitioners
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23106433. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-049-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/NCPD/CE/CPE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
StartThis activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 9, 2024; credit is no longer available.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
Media: Enduring Material
Activity Release Date: November 10, 2023
Activity Expiration Date: November 9, 2024
Time to Complete Activity: 30 minutes
Activity Description
The use of asparaginase as a component of multiagent chemotherapy has been clearly linked to optimal outcomes in pediatric acute lymphoblastic leukemia (ALL) populations. The approval of newer asparaginase formulations and dosing schedules has added to the growing collection of tools that clinicians can use to overcome challenges associated with consistent therapeutic exposure to asparaginase in ALL—but are you up to the task? This customizable, question-based activity covers the use of asparaginase compounds in pediatric ALL, the pitfalls of asparaginase discontinuation, and challenges such as hypersensitivity/silent inactivation. Test yourself and see if your choices will support the effective use of asparaginase as part of modern ALL therapy!
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, pharmacists, other healthcare professionals, and other clinicians involved in the care of patients with acute lymphoblastic leukemia.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the latest safety and efficacy evidence and unmet medical needs related to the optimal use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds
- Develop therapeutic plans for adequate asparaginase exposure that incorporate appropriate dosing, avoidance of truncation/discontinuation, and monitoring for hypersensitivity/toxicity or silent inactivation
- Implement team-based strategies to prevent therapy discontinuation or compromised patient outcomes in pediatric ALL, such as switching to alternative asparaginase formulations
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children's Hospital
Salt Lake City, Utah
Luke Maese, DO, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-070-H01-P
Type of Activity: Knowledge
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/9/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
StartThis activity expired on October 30, 2024; credit is no longer available.
Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
Media: Enduring Material
Activity Release Date: October 31, 2023
Activity Expiration Date: October 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to optimize the care of patients with small-cell lung cancer (SCLC) in the community setting with Dr. Ticiana Leal, as she reviews the latest therapeutic advances, guideline recommendations, and team-based best practices to offer practical insights on individualizing care for individuals with SCLC in your practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the characteristics, mechanisms of action, and efficacy/safety profiles of the latest therapeutic options for SCLC
- Develop individualized treatment plans for patients with SCLC based on the latest evidence-based practices, guideline recommendations, and patient needs and preferences that should inform and guide therapeutic decisions in different settings and lines of therapy
- Implement multidisciplinary and interprofessional strategies and shared decision-making to ensure the rapid, appropriate initiation of therapy and optimal care throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/30/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 30, 2024; credit is no longer available.
Optimizing the Care of Patients With SCLC in the Community Setting: How to Make the Most of the Latest Therapeutic Advances and Team-Based Best Practices
Media: Enduring Material
Activity Release Date: October 31, 2023
Activity Expiration Date: October 30, 2024
Time to Complete Activity: 60 minutes
Activity Description
Learn how to optimize the care of patients with small-cell lung cancer (SCLC) in the community setting with Dr. Ticiana Leal, as she reviews the latest therapeutic advances, guideline recommendations, and team-based best practices to offer practical insights on individualizing care for individuals with SCLC in your practice.
Target Audience
This activity has been designed to meet the educational needs of oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Analyze the characteristics, mechanisms of action, and efficacy/safety profiles of the latest therapeutic options for SCLC
- Develop individualized treatment plans for patients with SCLC based on the latest evidence-based practices, guideline recommendations, and patient needs and preferences that should inform and guide therapeutic decisions in different settings and lines of therapy
- Implement multidisciplinary and interprofessional strategies and shared decision-making to ensure the rapid, appropriate initiation of therapy and optimal care throughout the disease continuum for each patient with SCLC
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Ticiana Leal, MD, has a financial interest/relationship or affiliation in
the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Catalyst
Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono;
F-Hoffman LaRoche/Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz
Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis
Pharmaceuticals Corporation; Novocure, Inc.; Pfizer; Regeneron
Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Advaxis Immunotherapies; Bayer
Corporation; and Pfizer. Research funding goes to Institution.
Other Financial or Material Support from Regeneron Pharmaceuticals
Inc. for travel expenses.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/30/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
StartThis activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on November 26, 2024; credit is no longer available.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Media: Enduring Material
Activity Release Date: October 27, 2023
Activity Expiration Date: November 26, 2024
Time to Complete Activity: 60 minutes
Activity Description
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, nurses, pharmacists, and other clinicians involved in the management of MCL.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize the latest clinical evidence, mechanistic rationale, and current guidelines supporting the use of non-covalent BTKi agents in R/R MCL settings
- Integrate non-covalent BTK inhibitors into modern sequential treatment plans for R/R MCL, including in settings of BTKi-intolerant, or -resistant disease
- Develop collaborative protocols for addressing practical aspects of MCL care, including monitoring, patient education, and management of adverse events, when using BTKi strategies
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics
Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite,
A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis
Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.;
and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi
Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F.
Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.;
Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio,
Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead
Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly;
and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Pharmacists
PVI, PeerView Institute for Medical Education, designates this continuing
education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation
Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-064-H01-P
Type of Activity: Application
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 11/26/2024. PAs should only claim credit commensurate with the extent of their participation. |
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
For pharmacists, upon receipt of the completed activity evaluation form, you
will receive an email from email@email.peerviewpress.com within 2 weeks with
a link and directions to submit your credit to the NABP CPE Monitor Service.
PVI, PeerView Institute for Medical Education, will accept your completed
evaluation form for up to 30 days and will report your participation to the
NABP only if you provide your NABP e-Profile number and date of birth. Within
6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
StartThis activity expired on October 17, 2024; credit is no longer available.
Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
Media: Enduring Material
Activity Release Date: October 18, 2023
Activity Expiration Date: October 17, 2024
Time to Complete Activity: 60 minutes
Activity Description
Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other clinicians involved in the management of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction
- Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy
- Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jonathan I. Silverberg, MD, PhD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Jonathan I. Silverberg, MD, PhD, MPH, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Alamar Biosciences, Inc.;
Aldena Therapeutics; Amgen Inc.; AOBiome; Arcutis Biotherapeutics, Inc.;
Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals
Pte Ltd; BioMX; Biosion; Bodewell; Boehringer Ingelheim Pharmaceuticals,
Inc.; Cara Therapeutics; Castle Biosciences, Inc.; Celgene Corporation;
Connect Biopharma; Dermavant Sciences, Inc.; Dermira, Inc.; Dermtech;
Galderma S.A.; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; Leo Pharma;
Lilly; Menlo Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Optum,
Inc.; Pfizer; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi
Genzyme; Shaperon; and UNION therapeutics A/S.
Grant/Research Support from Galderma S.A.; Incyte; and Pfizer.
Speaker for Abbvie Inc.; Leo Pharma; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi Genzyme.
Co-Chair/Planner
Linda Stein Gold, MD
Director of Clinical Research
Department of Dermatology
Henry Ford Health
Detroit, Michigan
Division Head Dermatology
Henry Ford Health
West Bloomfield, Michigan
Linda Stein Gold, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi.
Patient Actor
Heather Mekulski
Heather Mekulski has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Gina Ostmann has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Javonte Perry
Javonte Perry has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23096339. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/17/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 17, 2024; credit is no longer available.
Bridging the Gap to Increased Patient Satisfaction in Moderate to Severe Atopic Dermatitis: Understanding the Role and Clinical Utility of Targeted Therapy
Media: Enduring Material
Activity Release Date: October 18, 2023
Activity Expiration Date: October 17, 2024
Time to Complete Activity: 60 minutes
Activity Description
Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, NPs, PAs, and other clinicians involved in the management of patients with atopic dermatitis.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction
- Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy
- Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Jonathan I. Silverberg, MD, PhD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Jonathan I. Silverberg, MD, PhD, MPH, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Alamar Biosciences, Inc.;
Aldena Therapeutics; Amgen Inc.; AOBiome; Arcutis Biotherapeutics, Inc.;
Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals
Pte Ltd; BioMX; Biosion; Bodewell; Boehringer Ingelheim Pharmaceuticals,
Inc.; Cara Therapeutics; Castle Biosciences, Inc.; Celgene Corporation;
Connect Biopharma; Dermavant Sciences, Inc.; Dermira, Inc.; Dermtech;
Galderma S.A.; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals; Leo Pharma;
Lilly; Menlo Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Optum,
Inc.; Pfizer; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi
Genzyme; Shaperon; and UNION therapeutics A/S.
Grant/Research Support from Galderma S.A.; Incyte; and Pfizer.
Speaker for Abbvie Inc.; Leo Pharma; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi Genzyme.
Co-Chair/Planner
Linda Stein Gold, MD
Director of Clinical Research
Department of Dermatology
Henry Ford Health
Detroit, Michigan
Division Head Dermatology
Henry Ford Health
West Bloomfield, Michigan
Linda Stein Gold, MD, has a financial interest/relationship or affiliation
in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics,
Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer;
Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Dermavant
Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Pfizer; Regeneron
Pharmaceuticals Inc.; and Sanofi.
Patient Actor
Heather Mekulski
Heather Mekulski has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Gina Ostmann
Gina Ostmann has no financial interests/relationships or affiliations in relation to this activity.
Patient Actor
Javonte Perry
Javonte Perry has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Partners
This activity has been developed in partnership with Healthcare Theatre from the University of Delaware.
Support
This activity is supported by an educational grant from Lilly.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners® (AANP). Activity ID# 23096339. This activity was planned in accordance with AANP Accreditation Standards and Policies. |
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/17/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/CE/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
StartThis activity expired on October 15, 2024; credit is no longer available.
Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
Media: Enduring Material
Activity Release Date: October 16, 2023
Activity Expiration Date: October 15, 2024
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac
disease, with a mortality rate estimated to be about three times greater than
that experienced by individuals of similar age without HCM. So far, the FDA
has approved only one noninvasive treatment option indicated for the
treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called
mavacamten. A second CMI, aficamten, is currently being studied. As timely
diagnosis of patients with HCM may reduce or delay the need for invasive
treatment, these treatment options are essential for cardiologists to
understand.
This PeerView activity covers what you need to know about diagnosing and
managing HCM for optimal patient care. A patient case threads through each
section and offers a window into real-world diagnostic and treatment
challenges as our expert shares guidance and the latest evidence. By the end
of this activity, you will be able to explain the underlying pathophysiology
of HCM, apply your new knowledge for timely diagnosis and individualized
treatment of HCM, and implement strategies for long-term patient safety and
improved outcomes.
Target Audience
This activity has been designed to meet the educational needs of cardiologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the care of patients with HCM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM
- Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM
- Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities
- Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol
Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon
Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics ; and
Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/15/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView
This activity expired on October 15, 2024; credit is no longer available.
Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice
Media: Enduring Material
Activity Release Date: October 16, 2023
Activity Expiration Date: October 15, 2024
Time to Complete Activity: 60 minutes
Activity Description
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac
disease, with a mortality rate estimated to be about three times greater than
that experienced by individuals of similar age without HCM. So far, the FDA
has approved only one noninvasive treatment option indicated for the
treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called
mavacamten. A second CMI, aficamten, is currently being studied. As timely
diagnosis of patients with HCM may reduce or delay the need for invasive
treatment, these treatment options are essential for cardiologists to
understand.
This PeerView activity covers what you need to know about diagnosing and
managing HCM for optimal patient care. A patient case threads through each
section and offers a window into real-world diagnostic and treatment
challenges as our expert shares guidance and the latest evidence. By the end
of this activity, you will be able to explain the underlying pathophysiology
of HCM, apply your new knowledge for timely diagnosis and individualized
treatment of HCM, and implement strategies for long-term patient safety and
improved outcomes.
Target Audience
This activity has been designed to meet the educational needs of cardiologists, advanced practice clinicians, nurses, and other healthcare professionals involved in the care of patients with HCM.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM
- Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM
- Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities
- Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Anjali Tiku Owens, MD, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol
Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon
Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics ; and
Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. |
Continuing Certification Statement
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Nurses
Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.
Physician Assistants
PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 10/15/2024. PAs should only claim credit commensurate with the extent of their participation. |
Method of Participation
There are no fees for participating in or receiving credit for this CE
activity. For information on applicability and acceptance of continuing
education credit for this activity, please consult your professional
licensing board.
A statement of credit will be issued only upon receipt of a completed
activity evaluation form and will be emailed to you upon completion. You will
receive your certificate from email@email.peerviewpress.com. If you have
questions regarding the receipt of your emailed certificate, please contact
via email at info@PeerView.com.
If requesting MOC/CC credit, the post-test and evaluation are required in
their entirety as well as your Board Unique ID number, DOB (MM/DD) (required
for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is
needed to obtain MOC/CC credit.
For nurses, the post-test and evaluation form are required in their entirety
and a score of 75% or higher is needed to obtain Nursing Continuing
Professional Development (NCPD) credit. There are no prerequisites and there
is no fee to participate in this activity or to receive NCPD credit.
Statements of Credit are awarded upon successful completion of the post-test
and evaluation form.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME/MOC/NCPD/AAPA Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2023, PeerView